Methylthioninium chloride Proveblue

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

methylthioninium chloride

Available from:

Provepharm SAS

ATC code:

V03AB17

INN (International Name):

methylthioninium chloride

Therapeutic group:

Il-prodotti terapewtiċi l-oħra kollha

Therapeutic area:

Metemoglobinemija

Therapeutic indications:

Trattament sintomatiku akut ta 'methaemoglobinaemia indotta minn prodotti mediċinali u kimiċi. Methylthioninium chloride Proveblue huwa indikat fl-adulti, it-tfal u l-adoloxxenti (b'età minn 0 sa 17-il sena).

Product summary:

Revision: 26

Authorization status:

Awtorizzat

Authorization date:

2011-05-06

Patient Information leaflet

                                20
B. FULJETT TA’ TAGĦRIF
21
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
_ _
METHYLTHIONINIUM CHLORIDE PROVEBLUE 5 MG/ML SOLUZZJONI GĦAL
INJEZZJONI
methylthioninium chloride
AQRA SEW DAN IL-FULJETT KOLLU QABEL TINGĦATA DIN IL-MEDIĊINA PERESS
LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-infermier
tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew l-infermier
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Methylthioninium chloride Proveblue u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tingħata Methylthioninium chloride
Proveblue
3.
Kif għandu jingħata Methylthioninium chloride Proveblue
4.
Effetti sekondarji possibbli
5.
Kif taħżen Methylthioninium chloride Proveblue
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU METHYLTHIONINIUM CHLORIDE PROVEBLUE U GĦALXIEX JINTUŻA
Il-methylthioninium chloride (li jissejjaħ ukoll methylene blue)
jagħmel parti minn grupp ta’ mediċini
li jissejħu antidoti.
Methylthioninium chloride Proveblue jingħata lilek jew
lit-tifel/tifla tiegħek (0-17-il sena) għall-kura
ta’ problemi fid-demm ikkawżati minn espożizzjoni għal ċerti
mediċini jew kimiċi li jistgħu
jikkawżaw marda li tissejjaħ metemoglobinemija.
Fil-metemoglobinemija, id-demm tiegħek ikun fih metemoglobina żejda
(forma mhux normali ta’
emoglobina li mhijiex kapaċi tittrasporta l-ossiġnu madwar il-ġisem
b’mod effettiv). Din il-mediċina
tgħin lill-emoglobina tiegħek tiġi lura għan-normal u tibda
mill-ġdid it-trasport tal-ossiġnu fid-demm.
2.
X’GĦANDEK TKUN TAF QABEL MA TINGĦATA METHYLTHIONINIUM CHLORIDE
PROVEBLUE
_ _
M’GĦANDEKX TINGĦATA METHYLTHIONINIUM CHLORIDE PROVEBLUE
-
jekk inti allerġiku/a għal methylthioninium chloride jew kuluri
thiazine oħrajn
-
jekk ġismek ma jipproduċix biżżejjed enzima G6PD
(glucose-6-p
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
_ _
2
1.
ISEM IL-PRODOTT MEDIĊINALI
_ _
Methylthioninium chloride Proveblue 5 mg/ml soluzzjoni għal
injezzjoni
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Kull ml tas-soluzzjoni fih 5 mg methylthioninium chloride.
Kull fjala ta’ 10 ml fiha 50 mg methylthioninium chloride.
Kull fjala ta’ 2 ml fiha 10 mg methylthioninium chloride.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Soluzzjoni għal injezzjoni (injezzjoni)
Soluzzjoni ċara ta’ lewn blu skur bil-valur ta’ pH ta’ bejn 3.0
u 4.5
L-osmolalità hija normalment bejn 10 u 15 mOsm/kg.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Kura għas-sintomi akuti ta’ metemoglobinemija indotta minn prodotti
mediċinali u kimiċi.
Methylthioninium chloride Proveblue huwa indikat fl-adulti, fit-tfal u
fl-adolexxenti (ta’ bejn iż-0 u s-
17-il sena).
_ _
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Methylthioninium chloride Proveblue
għandu jingħata minn professjonista tal-kura tas-saħħa.
Pożoloġija
_ _
_Adulti _
_ _
Id-doża normali hija ta’ 1 sa 2 mg għal kull kg ta’ piż
tal-ġisem, jiġifieri 0.2-0.4 ml għal kull kg ta’ piż
tal-ġisem, mogħtija fuq perjodu ta’ 5 minuti.
Doża ripetuta (1 sa 2 mg/kg piż tal-ġisem, jiġifieri 0.2-0.4 ml/kg
piż tal-ġisem) tista’ tingħata siegħa
wara l-ewwel doża f’każ ta’ sintomi persistenti jew rikorrenti
jew jekk il-livelli ta’ metemoglobina
jibqgħu sostanzjalment ogħla mill-medda klinika normali.
Normalment il-kura ma tkunx ta’ aktar minn ġurnata.
Id-doża kumulattiva massima rakkomandata għall-kors tat-trattament
hija ta’ 7 mg/kg u m’għandhiex
tinqabeż, minħabba li Methylthioninium chloride mogħti aktar
mid-doża massima jista’ jikkawża
metemoglobinemija f’pazjenti suxxettibbli.
Fil-każ ta’ metemoglobinemija indotta mill-anilina jew mid-dapsone,
id-doża kumulattiva massima
rakkomandata għall-kors tal-kura hija ta’ 4 mg/kg (ara sezzjoni
4.4).
Hemm ftit wisq de
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 14-03-2024
Public Assessment Report Public Assessment Report Bulgarian 07-05-2018
Patient Information leaflet Patient Information leaflet Spanish 14-03-2024
Public Assessment Report Public Assessment Report Spanish 07-05-2018
Patient Information leaflet Patient Information leaflet Czech 14-03-2024
Public Assessment Report Public Assessment Report Czech 07-05-2018
Patient Information leaflet Patient Information leaflet Danish 14-03-2024
Public Assessment Report Public Assessment Report Danish 07-05-2018
Patient Information leaflet Patient Information leaflet German 14-03-2024
Public Assessment Report Public Assessment Report German 07-05-2018
Patient Information leaflet Patient Information leaflet Estonian 14-03-2024
Public Assessment Report Public Assessment Report Estonian 07-05-2018
Patient Information leaflet Patient Information leaflet Greek 14-03-2024
Public Assessment Report Public Assessment Report Greek 07-05-2018
Patient Information leaflet Patient Information leaflet English 14-03-2024
Public Assessment Report Public Assessment Report English 07-05-2018
Patient Information leaflet Patient Information leaflet French 14-03-2024
Public Assessment Report Public Assessment Report French 07-05-2018
Patient Information leaflet Patient Information leaflet Italian 14-03-2024
Public Assessment Report Public Assessment Report Italian 07-05-2018
Patient Information leaflet Patient Information leaflet Latvian 14-03-2024
Public Assessment Report Public Assessment Report Latvian 07-05-2018
Patient Information leaflet Patient Information leaflet Lithuanian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 14-03-2024
Public Assessment Report Public Assessment Report Lithuanian 07-05-2018
Patient Information leaflet Patient Information leaflet Hungarian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 14-03-2024
Public Assessment Report Public Assessment Report Hungarian 07-05-2018
Patient Information leaflet Patient Information leaflet Dutch 14-03-2024
Public Assessment Report Public Assessment Report Dutch 07-05-2018
Patient Information leaflet Patient Information leaflet Polish 14-03-2024
Public Assessment Report Public Assessment Report Polish 07-05-2018
Patient Information leaflet Patient Information leaflet Portuguese 14-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 14-03-2024
Public Assessment Report Public Assessment Report Portuguese 07-05-2018
Patient Information leaflet Patient Information leaflet Romanian 14-03-2024
Public Assessment Report Public Assessment Report Romanian 07-05-2018
Patient Information leaflet Patient Information leaflet Slovak 14-03-2024
Public Assessment Report Public Assessment Report Slovak 07-05-2018
Patient Information leaflet Patient Information leaflet Slovenian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 14-03-2024
Public Assessment Report Public Assessment Report Slovenian 07-05-2018
Patient Information leaflet Patient Information leaflet Finnish 14-03-2024
Public Assessment Report Public Assessment Report Finnish 07-05-2018
Patient Information leaflet Patient Information leaflet Swedish 14-03-2024
Public Assessment Report Public Assessment Report Swedish 07-05-2018
Patient Information leaflet Patient Information leaflet Norwegian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 14-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 14-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 14-03-2024
Patient Information leaflet Patient Information leaflet Croatian 14-03-2024
Public Assessment Report Public Assessment Report Croatian 07-05-2018

Search alerts related to this product